Streetbeat News

Analyst Ratings

ON

Mizuho analyst Vijay Rakesh maintains a Buy rating on ON Semiconductor (NASDAQ:ON) but lowers the price target from $98 to $92.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 7:24 pm

VRTX

JP Morgan analyst Jessica Fye maintains an Overweight rating on Vertex Pharmaceuticals (NASDAQ: VRTX) and raises the price target from $438 to $450.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 7:24 pm

FMC

Mizuho analyst Christopher Parkinson maintains a Neutral rating on FMC Corporation (NYSE:FMC) and lowers the price target from $59 to $55.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 7:23 pm

CCK

Mizuho analyst John Roberts maintains a Buy rating on Crown Holdings (NYSE:CCK) but lowers the price target from $105 to $96.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 7:21 pm

VRNS

JP Morgan analyst Brian Essex maintains a Neutral rating on Varonis Systems (NASDAQ:VRNS) and raises the price target from $49 to $50.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 7:19 pm

ABBV

AXSM

BMY

UBS initiated coverage on Axsome Therapeutics Inc (AXSM) with a Buy rating and a price target of $111, citing bullish prospects for its depression drug Auvelity and pipeline opportunities. UBS anticipates Auvelity could generate $1 billion in sales by 2030. Positive Phase 3 trial data for Alzheimer's Agitation and Narcolepsy could further boost AXSM's stock. The sector sees increased investor interest after Bristol Myers Squibb (BMY) and AbbVie (ABBV) made significant acquisitions. Axsome's Q4 2023 revenue is preliminarily reported at $71 million, with full-year revenue at $204 million.

Portfolio Pulse from Vandana Singh

February 06, 2024 | 7:19 pm

APD

Mizuho analyst Christopher Parkinson maintains a Buy rating on Air Products & Chemicals (APD) but lowers the price target from $304 to $295.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 7:19 pm

TSN

JP Morgan analyst Kenneth Goldman maintains a Neutral rating on Tyson Foods (NYSE:TSN) and raises the price target from $55 to $58.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 7:18 pm

ADVM

Mizuho analyst Graig Suvannavejh maintains a Buy rating on Adverum Biotechnologies (ADVM) and raises the price target from $2 to $4.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 7:16 pm

EL

JP Morgan analyst Andrea Teixeira maintains an Overweight rating on Estee Lauder Cos (EL) and raises the price target from $150 to $167.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 7:14 pm